SCYNEXIS, Inc. Alternatives & Competitors
12 companies similar to SCYNEXIS, Inc. — Advancing innovative solutions for severe rare diseases
Companies similar to SCYNEXIS, Inc.
Forma Therapeutics
Dedicated to transforming the lives of patients with rare hematologic diseases and cancers...
Watertown, United States
Neumora
Pioneering a new era of medicines for brain diseases
Watertown, United States
Dualyx
Discovery and development of highly innovative biologicals for the treatment of autoimmune...
Belgium
Angitia Biopharmaceuticals
Developing innovative medicines to address serious musculoskeletal diseases
Westlake Village, United...
Rival Readout
Competing with SCYNEXIS, Inc.? We do this properly.
10 rivals, 90 days of dated moves, ranked by what matters and sourced, in 7 business days.
VectivBio
Biotech company develops treatments for severe rare diseases, aims to become global leader...
Basel, Switzerland
Vyome Holdings, Inc.
Vyome is building the world’s premier biotech, AI-healthcare platform spanning the US-Indi...
Cambridge, United States
Biomed Valley Discoveries
Biotech, Purposefully Reimagined
Kansas City, United State...
Ultragenyx
Going Beyond Every Day
Novato, United States
Calliditas Therapeutics
Pioneering treatments for rare diseases. We harness scientific & commercial expertise to i...
Stockholm, Sweden
Pharma Two B
Clinical stage pharma company striving to improve patients quality of life by developing i...
Rehovot, Israel
PaxMedica, Inc.
Empowering Possibilities, Transforming Lives: PaxMedica's Journey in Neurodevelopmental So...
Tarrytown, United States
Ascendis Pharma
Committed to making a meaningful difference for patients
Denmark
About SCYNEXIS, Inc.
SCYNEXIS, Inc., founded in 2000, is a biotechnology company dedicated to providing innovative solutions for patients with severe, progressive, and underserved rare diseases. Their commitment to addressing significant unmet medical needs highlights the company's potential for differentiated innovation in the biotech sec...
Development of AMPK activators, Creation of antifungal triterpenoids, Research and development in rare diseases, Clinical trial execution, Pharmaceutical innovation
Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD), Individuals vulnerable to severe fungal infections, Healthcare providers focusing on rare diseases, Biotech and pharmaceutical industry partners
Rare Diseases, Severe Rare Diseases, Progressive Rare Diseases, Clinical-Stage Assets, Drug Development, Therapeutic Innovation, Unmet Medical Needs, Infectious Diseases, Fungal Diseases, Targeting Underlying Biology, Patient-Centric Solutions, Advancing Clinical Programs, Scientific Expertise, Disciplined Drug Development
B2B
Product Sales, Licensing, Performance Based
Frequently Asked Questions
From the desk
Mapping a market? Start with a Rival Readout.
In 7 business days we read 10 rivals around SCYNEXIS, Inc.: 90 days of dated moves, ranked by what matters to you, each with its source. Fully credited if you continue.
Compiled from the BounceWatch company index. We last looked at SCYNEXIS, Inc. on 9 Jun 2026. The 12 companies listed here were last checked between 11 Sep 2024 and 9 Jun 2026. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.
